key: cord-0831521-edk2xeh0
authors: Drury, Broc; Hardisty, Gareth; Gray, Robert D.; Ho, Gwo-tzer
title: Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation
date: 2021-03-06
journal: Cell Mol Gastroenterol Hepatol
DOI: 10.1016/j.jcmgh.2021.03.002
sha: 3659727546996e9205ca91adc4b650e4ad327c2e
doc_id: 831521
cord_uid: edk2xeh0

The Inflammatory Bowel Diseases (IBD), Ulcerative Colitis (UC) and Crohn’s Disease (CD) are characterised by chronic non-resolving gut mucosal inflammation involving innate and adaptive immune responses. Neutrophils, usually regarded as first responders in inflammation, are a key presence in the gut mucosal inflammatory milieu in IBD. Here, we review the role of neutrophil extracellular trap (NET) formation as a potential effector disease mechanism. NETs are extracellular webs of chromatin, microbicidal proteins and oxidative enzymes that are released by neutrophils to contain pathogens. NETs contribute to the pathogenesis of several immune-mediated diseases such as systemic lupus erythematosus and rheumatoid arthritis; and recently, as a major tissue damaging process involved in the host response to severe acute respiratory syndrome coronavirus 2 infection. NETs are pertinent as a defence mechanism at the gut mucosal interphase exposed to high levels of bacteria, viruses and fungi. On the other hand, NETs can also potentiate and perpetuate gut inflammation. In this review, we discuss the broad protective vs. pathogenic roles of NETs, explanatory factors that could lead to an increase in NET formation in IBD and how NETs may contribute to gut inflammation and IBD-related complications. Finally, we summarise therapeutic opportunities to target NETs in IBD.

U lcerative colitis (UC) and Crohn's disease (CD) are 2 clinical entities that define the inflammatory bowel diseases (IBD). Both are chronic immune-mediated conditions with rapidly increasing global incidence. 1 Although displaying different clinical features, they share a nonresolving pattern of gut mucosal inflammation. Current therapeutic approaches are focused on inhibiting the aberrant gut inflammation and immune response. For example, blocking inflammatory cytokines such as tumor necrosis factor alpha (TNF-a) and interleukin (IL)-23, the migration of leukocytes with anti-a4b7 integrin therapies, T cell responses with thiopurines, and downregulating general inflammation with glucocorticoids. Notwithstanding recent therapeutic advances in IBD, primary treatment failure is common, and complete mucosal healing is achieved in 50% of patients with moderate-to-severe IBD. Hence, a creative appraisal encompassing distinct mechanistic pathways is necessary in the design of future treatment strategies beyond mitigating downstream inflammatory responses. 2 Although prominently featured in the inflamed IBD mucosa, the translational potential of targeting the damaging effects of neutrophils is relatively understudied. A notable inflammatory process driven by neutrophils is mediated via their ability to form neutrophil extracellular traps (NETs). NETs comprise of a scaffold of DNA laced with histones and cytotoxic neutrophil-derived proteins and are released by neutrophils during infection and inflammation to contain invading microbes as a protective response. [3] [4] [5] NET components are indiscriminately cytotoxic and proinflammatory and thus can play an active role in a wide range of pathologies involved in autoimmunity, thrombosis, and cancer ( Figure 1 ). 6 Here, we focus on the role of the neutrophils and how their ability to form NETs presents an area for clinical translation in IBD. resolution of inflammation, repair, and a return to normal tissue function. [8] [9] [10] Persistent activation and overexuberant recruitment of neutrophils are common features in many inflammatory diseases. Neutrophils produce a wide variety of chemokines, cytokines, and leukotrienes, allowing them to recruit and activate a broad spectrum of immune cells. 11, 12 Neutrophils also directly cause tissue damage by releasing proteases such as matrix metalloproteases and neutrophil elastase (NE), 13, 14 as well as from oxidative burst which directly disrupts cell membranes. 15 Neutrophils play an important role in IBD gut inflammation. They produce high levels of reactive oxygen species (ROS) that cause epithelial barrier damage and can activate redox-sensitive inflammatory pathways. 16 They also released a host of proteases, proinflammatory cytokines and mediators such as IL-8, TNF-a, and leukotriene B 4 that damage the epithelial barrier and recruit monocytes and more neutrophils to the gut. 17, 18 Neutrophil infiltration correlates with disease activity in IBD [19] [20] [21] [22] [23] and is a widely used and reliable component of UC disease scoring systems. 24 Calprotectin (s100A8/9), the most widely used biomarker in IBD, constitutes up to 60% of neutrophil cytosolic proteins. 25, 26 In addition, many more neutrophil-derived IBD biomarkers have been proposed, [27] [28] [29] and there are several examples of neutrophil-targeted therapies. Although a neutrophil response is strongly featured in UC, 30 in CD, neutrophil function may be impaired with reduced migration, superoxide production, and phagocytic functions. 31, 32 In contrast to UC, reduced neutrophil accumulation and delayed bacterial clearance is observed at sites of injury within the gut and systemically in CD. 33 This suggests that the development of chronic inflammation and granuloma formation is a consequence of an impaired innate immune response in CD. 33, 34 In this regard, similar features are seen in chronic granulomatous disease and glycogen storage disease that are characterized by deficient neutrophil responses. 32, 35 NET Formation Brinkmann et al 3 first discovered NETs upon stimulating neutrophils with IL-8, phorbol-12-myrisate-13-acetate (PMA), or lipopolysaccharide (LPS). NETs prevent the spread of a range of pathogens 5 by trapping them in an environment of microbicidal components and prevent fungal growth as has been demonstrated with Candida albicans. 4 NETs contain granule proteins, histones, cytoplasmic proteins, and notably, calprotectin, which is important in antifungal defence. 4 Extracellular traps are an effective and highly conserved defence mechanism. 36 They have been reported in teleosts, 37 chickens, 38 crabs, and mussels, 39 and in plants as part of the root tip resistance to fungal infection, 40 and many pathogens have evolved mechanisms to repulse 41 or degrade them. 42, 43 Given the proximity of the gut mucosa to the microbiota, the role of NETs is of particular importance in IBD as an integral component of the host defense ( Figure 2 ).

Although interest in NETs grows, a refined consensus on NET mechanisms and classification is lacking. 44, 45 From a recent expert review, 44 a few aspects are noteworthy; first NETosis does not cover all forms of NET release and the term NET formation is preferred. Second, there are many in vivo NET stimulants including bacteria, fungal hyphae, cytokines, immune complexes, and activated platelets. Third, there are 2 broad mechanistic pathways for NET formation: late lytic, occurring 2-4 hours poststimulus, which is most commonly induced by PMA and results in neutrophil death, and early nonlytic, which occurs 5-60 minutes poststimulus induced by, for example, Toll-like receptors (TLRs) responding to pathogen associated molecular patterns and not resulting in neutrophil death. However, the mechanisms underlying NET formation differ considerably within these general pathways, depending on stimulant. 46, 47 For instance, PMA-induced NET formation requires protein kinase C activation, calcium flux, ROS, myeloperoxidase (MPO) and NE but bacteria-derived ionophore-induced NET formation can work independently of protein kinase C activation, ROS, MPO, or NE. 46 Because NETs with a similar makeup can be induced by very different stimuli, pinpointing what triggers increased NET formation in a pathogenic manner is challenging in gut inflammation and IBD. For instance, disparate factors such as C albicans and PMA can both stimulate the release of NETs containing calprotectin, a known biomarker in IBD. 4 However, there may be other ways to pinpoint stimulants. Bacterial factors (eg, N-formylated peptides) may induce the release of different granule types and measuring the levels of primary vs secondary granule proteins such as the ratio of myeloperoxidase to lactoferrin in IBD, may provide insights into the types of neutrophil stimulants in general and therefore NET stimulants. 48 

As with many host protective mechanisms, the deployment of NETs can be a double-edged sword. 6, 49 NETs can promote or prolong both innate and adaptive immune responses in a wide variety of diseases ( Figure 1 ). In cystic fibrosis, NETs directly induce IL-8 and TNF-a production by monocyte-derived macrophages, 50 and in atherosclerosis, NETs augment IL-1b and IL-6 production by monocytes stimulated with cholesterol crystals. 51 In rheumatoid arthritis (RA), NETs provide a scaffold for autoantibodies against citrullinated histones, 52 and in systemic lupus erythematosus (SLE), NETs containing LL-37 and high-mobility group box 1 can trigger plasmacytoid dendritic cell production of interferon alfa. 53 NETs can also facilitate thrombosis in vasculitis by providing a framework for platelet and tissue factor adhesion. 54 NETs augment cancer progression by trapping and spreading cancerous cells and polarizing neutrophils toward an immunosuppressive N2-like population. 55, 56 Finally, NETs contribute to sustained proinflammatory cytokine production, mucous secretion, and thrombosis in COVID-19 (coronavirus disease 2019). 57, 58 

To date, 8 studies (Table 1) have demonstrated an increased presence of NETs in the inflamed gut mucosa, stool, or blood in IBD, 4 of which stipulate that NET abundance is positively correlated with active disease. 64, 66, 69, 70 Liquid chromatography-mass spectrometry-based IBD proteomics studies reveal an increase in key NET proteins such as myeloperoxidase (MPO) and NE, both of which are highly specific to neutrophils and involved in chromatin decondensation during NET formation, 71 as well as increased calprotectin and cathepsin G, both of which have been found in NETs 4 in both intestinal biopsies 72 and fecal samples. 73 Increased levels of NET-associated proteins in IBD have also been demonstrated by immunofluorescence, immunohistochemistry, or Western blot in intestinal biopsies 60, 65, 66, 69 as well as in the colonic mucosa of experimental colitis in mice. 70 Using Western blot, these increased NET-specific proteins included NE, MPO, and citrullinated histone H3, another widely used NET biomarker, 66,74 and using immunofluorescence, NETs have been found as DNA complexed with NE, MPO, and histones. 60, 65, 66, 69 Additionally, increased NET components have been found in the circulation of IBD patients 69,70 by capture enzymelinked immunosorbent assay that measured DNA bound to MPO as a surrogate marker of a NET. Although these findings are important, colocalization or correlation of DNA with NET-implicated proteins is not outright evidence of NET formation because DNA of any source can bind proteins released from neutrophils through several processes including apoptosis and degranulation, and more rigorous qualification and quantification is suggested in Box 1. Is increased NET formation a shared phenomenon in UC and CD? Several studies have reported this in both entities, 60, 64, 69, 70, 73 while others found no evidence in CD. 65, 66 Different experimental methods and patient cohorts may explain some of the discrepancies. For instance, Dinallo et al 66 ruled out an increase in NETs in CD intestinal biopsies based on the absence of increased expression of peptidylarginine deiminase 4 (PAD4), a nuclear citrullinating enzyme classically believed to be essential for NET formation. However, it has been proven that PAD4 is not required for all forms of NET release, as shown with C albicans and group B Streptococcus-mediated NET formation. 44, 46 However, as UC is typically associated with higher neutrophil recruitment, 30, 33 if true, the finding of increased NETs in UC relative to CD is perhaps not unexpected.

Increased NET abundance is also not unique or specific to IBD and is likely present in any situation in which there is significant neutrophil involvement and gut microbial exposure. For instance, in necrotizing enterocolitis, in which gut barrier defense is markedly compromised by inflammation, high levels of NETs can be found in gut tissue. 75 However, higher levels of proteins associated with NETs including MPO, NE, and calprotectin can differentiate individuals with IBD from those with noninflammatory conditions such as irritable bowel syndrome in fecal metaproteomic studies, 73 suggesting that increased NET production in the IBD is related to gut inflammation.

Are Neutrophils in IBD More Likely to Form NETs?

Are neutrophils in IBD more prone to forming NETs? Several angles are noteworthy. First, the local biological microenvironment is crucial. For instance, in diabetes, a hyperglycemic environment primes NET formation by upregulating PAD4, 76 and in SLE, circulating microparticles derived from apoptotic cells can increase the potential for NET formation. 77 Serum from patients with UC and CD; and media from ex vivo culture of inflamed UC mucosa can stimulate higher spontaneous NET formation. 64, 65 This suggests the involvement of inflammatory mediators in the circulation and PAMPs, pathogen-associated molecular patterns.

from the mucosa, but triggers by transmigrated gut microbial components such as bacterial DNA [78] [79] [80] are also likely stimuli.

Second, are there intrinsically distinct neutrophil phenotypes in IBD that are more prone to NET formation? Disease-specific neutrophil subsets such as type I interferon hyperresponsive neutrophils in SLE 81 or low-density neutrophils, implicated in a variety of diseases 82,83 that are considered more susceptible to form NETs, have been described. He et al 64 found that neutrophils, irrespective of whether they are obtained from UC, CD, or non-IBD subjects, had similar NET formation capacity when stimulated with IBD sera. Dinallo et al 66 demonstrated that in vitro NET formation capacity by active UC neutrophils is similar to healthy controls in response to a variety of stimulants including TNF-a, LPS, and PMA. However, 3 studies provided contrary evidence, stating that in vitro, neutrophils from CD and UC 70 or from UC alone 65,69 have a primed or intrinsically increased NET formation capacity, reported as spontaneous 65, 70 or PMA induced. 69 Of interest, NET-prone CD177þ neutrophils are found in increased proportions in the blood and inflamed intestinal mucosa of both UC and CD patients. 22, 84 CD177 is a glycoprotein that is exclusively expressed on neutrophils, neutrophilic myelocytes, and metamyelocytes. CD177 is involved in neutrophil transmigration and is upregulated upon acute bacterial infection. 85 CD177þ neutrophils have a higher expression of granule protein genes 86 and are an activated or primed subset in several diseases including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), SLE, and asthma. 87, 88 In IBD, CD177þ neutrophils have a shifted gene expression profile toward microbial defense and release more ROS, MPO, and calprotectin, and produce more NETs than CD177-neutrophils. 22 Notably CD177þ neutrophils in inflamed mucosa of CD and UC patients positively correlate with Crohn's Disease Activity Index and UC Mayo Score. 22 Third, are there increased numbers of aged neutrophils in IBD that are more likely to form NETs? Neutrophil lifespan can be prolonged by growth factors, cytokines, and microbial products during infection and inflammation. 89, 90 Delayed apoptosis leads to the persistence of autoantigens in RA and AAV, 8 enhanced risk of tissue damage in acute coronary syndromes, 91 and enhanced NET formation capacity in cystic fibrosis. 50 In IBD, spontaneous neutrophil apoptosis is delayed by IL-8 and granulocyte colony-stimulating factor. 92, 93 With relevance to IBD, it has been reported that a systemic, aged, proinflammatory neutrophil population with higher NET formation capacity, defined as a CD62L lo CXCR4 hi subset, can be driven by the gut microbiota via TLRs and myeloid differentiation factor 88-mediated pathways in mice. 94 This population is diminished upon depletion of the microbiota with antibiotics. 94 

The composition of NETs and their specific effects is a further factor to consider above abundance alone. For instance, in psoriasis, NETs containing proinflammatory LL-37-DNA complexes activate plasmacytoid dendritic cells, leading to increased interferon alfa production. 49 In RA, autoantibodies against NET components such as citrullinated vimentin are found in the circulation leading to augmentation of IL-6 and IL-8 inflammatory responses 52 and in SLE, NETs are embedded with highly proinflammatory oxidized mitochondrial DNA (mtDNA), which stimulates type I interferon signaling through the DNA sensor stimulator of interferon genes. 95 In 2018, Angelidou et al 65 described bioactive IL-1bdecorated NETs in UC but not in CD. These IL-1b-containing NETs formed through an autophagy-dependent mechanism that facilitates the extrusion of NET contents. 44 Here, they showed that IL-1b-decorated NET production was linked to the expression of DNA damage inducible transcript 4 (DDIT4) in UC. 65 DDIT4 is an important, ubiquitously expressed stress-response mammalian target of rapamycin inhibitor linking cellular stress to autophagy-mediated NETassociated IL-1b responses in familial Mediterranean

To achieve better clarity in future work, several experimental considerations are noteworthy.

1. Multiple characterization of NET components beyond the use of single NET markers such as PAD4 are needed. Ideal methodology would combine the use of sandwich enzyme-linked immunosorbent assays for blood work, targeting DNA-MPO/citH3/NE complexes, 59 colocalization studies in tissue using immunohistochemistry, 60 intravital microscopy, and live cell imaging. 61, 62 2. For NET formation studies, neutrophils must be isolated with an appreciation of the ability of calcium, magnesium, and chelators to alter NET formation capacity. 44, 63 fever. 96 DDIT4 expression was higher in UC neutrophils and in control neutrophils stimulated with UC colon tissue culture media. 65 It was proposed that this DDIT4/NET/IL-1b pathway may be specific to UC (not CD) as a form of IL-1b autoinflammatory disease. Angelidou et al 96 previously described that in familial Mediterranean fever, neutrophils undergo autophagy-mediated NET formation via the DDIT4 pathway through stress mediators such as epinephrine.

Studying the effects of similar stress mediators on NET formation may also be relevant in UC.

ANCAs may play a role in NET-mediated IBD pathology. ANCAs drive the development of AAV in which they target proteinase 3 (PR3) or MPO 97 and initiate neutrophil-rich necrotizing inflammation, causing organ damage. 98 In UC, the perinuclear type, pANCA, is found in up to 80% of UC patients, 99,100 with a distinct subset of UC-specific ANCAs, DNase I-sensitive ANCAs, known for targeting only nuclear-protein complexes. 99, 101 This UC-derived DNase I-sensitive ANCA can bind to antigens present on NETs. 102 In 2016, He et al 64 showed that NET formation is amplified when neutrophils were incubated with ANCA-IgG isolated from active PR3-ANCA-positive IBD patients. In addition, Li et al 69 proposed a further mechanism, in which ANCAs decreased the breakdown of NETs, by attenuating DNase I activity particularly during active IBD. Finally, ANCAs in IBD might activate neutrophils through Fc receptor stimulation when binding granule components such as PR3 or MPO, which have been translocated to their outer membrane during activation, as described with AAV. 101, 103 Are There Proinflammatory Mitochondrial NETs in IBD?

Another area of significant interest in NET-driven pathology is the existence of NETs embedded with NET-associated proteins increased in colonic mucosa: lactoferrin, MPO, NE, calprotectin, neutrophil defensin 3-UC.

Lehmann et al 73 mitochondrial DNA (mtNETs). This is relevant as an association of increased mtDNA levels with active UC and CD have been reported. 104 mtNET formation has been described as early, nonlytic, and ROS dependent and was originally demonstrated with neutrophils primed by granulocyte-macrophage colony-stimulating factor followed by TLR4 or complement receptor activation. 105 Here, NETs were found to contain mitochondrial DNA and the granule proteins NE and MPO but, interestingly, not genomic DNA. Yousefi et al 55 recently proposed mtNETs are an active, proinflammatory, antimicrobial tool that utilize mtDNA fragments no longer needed within the cell in combination with granule proteins, suggesting that they are true nonlytic NETs. Although the mechanisms remain unknown, mtNETs are now supported by many as an alternative form of NET release, 5 although they should be carefully differentiated from incomplete mitophagy, which can lead to the release of oxidized nucleoids containing mitochondrial components following cell damage. 106 Their similarities with bacteria point to mitochondrial components within mtNETs as potent inflammatory mediators 107, 108 and oxidized mtDNA and mtNETs have now been implicated in a range of diseases, including SLE and chronic granulomatous disease 95 and in sterile injury, surgery, 109 and cancer. 110

One potential implication of increased circulating NETs in IBD is an increased thrombotic risk. Both UC and CD patients have an increased (3-fold) risk of thromboembolic events compared with the general population. 111 Although abnormalities in coagulation and fibrinolytic systems such as elevated circulating fibrinogen, prothrombin, and microparticles have been found, these abnormalities are insufficient to explain the increased thromboembolic risk in IBD. 111 Recently, 3 separate studies have linked NETs to increased thrombotic tendency in IBD. 64, 69, 70 In 2016, He et al 64 found that NETs contributed to increased coagulation, which could be counteracted by DNase I. Here, they highlighted that NET NE can inactivate tissue factor inhibitor and that NETs provide a scaffold for platelet and erythrocyte adhesion. The same group went on to demonstrate that incubating normal platelets with NETs from active IBD patients enhanced procoagulant activity by 32% and the ability to support fibrin formation by 42%. 70 Recently, they reported the treatment of a dextran sulfate sodium-induced mouse colitis model with DNase I led to lower disease activity and a decrease in prothrombotic effects. 69 Intriguingly, they also found ANCA-IgG to have a role, inducing NET formation as well as microparticle shedding by cultured endothelial cells, which accelerated Other approaches -Antibody-mediated targeting of NETs for macrophage degradation. 128 Not only breaks down DNA but also proinflammatory/destructive NET proteins. -Cross-linking of NET-inhibitory receptors such as signal inhibitory receptor on leukocytes-1. 129 Inhibits NETs but preserves intracellular bacterial killing.

ANCA, antineutrophil cytoplasmic antibody; ASUC, acute severe ulcerative colitis; DSS, dextran sulfate sodium; FMF, familial Mediterranean fever; IASO, Interleukin 1 blockade in Acute Severe Colitis; IBD, inflammatory bowel disease; IL, interleukin; MPO, myeloperoxidase; NET, neutrophil extracellular trap; RA, rheumatoid arthritis; TNF-a, tumor necrosis factor alpha.

coagulation. 8 The effect of NETs on prothrombotic tendencies in IBD is a novel area and may have similarities to other diseases such as vasculitis. 54, 112 Beneficial Roles of NETs in IBD NETs have been shown to play a beneficial role in downregulating inflammation in several conditions. In RA, NETs can downregulate IL-6 and upregulate IL-10 secretion in LPS-activated macrophages. 113 In gout, NETs contribute to the resolution of inflammation directly by degrading cytokines and chemokines via serine proteases and when NET formation is impaired, the propensity of monosodium urate crystals, the trigger for gout, to activate neutrophils is amplified. 114 Proteases within NETs have been shown to be efficient regulators of cytokine activity in vitro and in vivo and will also play a role in regulating a large number of cytokines in IBD. 115 Finally, circulating NETs may have a role in clearing damage-associated molecular patterns such as transmigrated bacterial components, 78-80 a mechanism proven in murine sepsis. 62 Thus, some care must be taken in targeting NETs as a therapy in IBD.

The knowledge of NET biology has allowed new insights into the inflammatory processes of many diseases. Although NET formation is a relatively unexplored area in IBD, it presents an excellent opportunity to understand the potential contribution of a major immune cell, the neutrophil, in the pathogenic and nonresolving gut inflammation in IBD. Importantly, the development of NET-targeted therapies in IBD can draw on lessons from other diseases (summarized in Table 2 ). Targeting NETs may form a novel treatment approach to achieving complete mucosal healing in IBD.

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

Resolution of inflammation and gut repair in IBD: translational steps towards complete mucosal healing

Neutrophil extracellular traps kill bacteria

Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans

Killing by neutrophil extracellular traps: fact or folklore?

An emerging role for neutrophil extracellular traps in noninfectious disease

Getting to the site of inflammation: the leukocyte adhesion cascade updated

Regulation of human neutrophil apoptosis and lifespan in health and disease

Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages

The role of macrophages in the resolution of inflammation

Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF-alpha, and IL-1 beta

G-CSF-stimulated neutrophils are a prominent source of functional BLyS

N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD

Aalpha-Val360: a marker of neutrophil elastase and COPD disease activity

The multifactorial role of neutrophils in rheumatoid arthritis

Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets

The dual role of neutrophils in inflammatory bowel diseases

Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease

Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis

Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation

Validation of neutrophil CD64 blood biomarkers to detect mucosal inflammation in pediatric Crohn's disease

CD177þ neutrophils as functionally activated neutrophils negatively regulate IBD

Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial

Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization

Use of biomarkers in inflammatory bowel disease

Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications

Faecal neutrophil elastase-antiprotease balance reflects colitis severity

Fecal serine protease profiling in inflammatory bowel diseases

Ulcerative colitis is characterized by amplified acute inflammation with delayed resolution

The neutrophil respiratory burst and bacterial digestion in Crohn's disease

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenisis of Crohn's disease

Studies on patients establish Crohn's disease as a manifestation of impaired innate immunity

Disruption of macrophage proinflammatory cytokine release in Crohn's disease is associated with reduced optineurin expression in a subset of patients

Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease

Extracellular traps: an ancient weapon of multiple kingdoms

Zebrafish (Danio rerio) whole kidney assays to measure neutrophil extracellular trap release and degranulation of primary granules

Chicken heterophil extracellular traps (HETs): Novel defense mechanism of chicken heterophils

Invertebrate extracellular phagocyte traps show that chromatin is an ancient defence weapon

Extracellular DNA is required for root tip resistance to fungal infection

Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps

DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps

Nuclease expression by Staphylococcus aureus facilitates escape from neutrophil extracellular traps

To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps

Untangling "NETosis" from NETs

Diverse stimuli engage different neutrophil extracellular trap pathways

vitro induction of NETosis: comprehensive live imaging comparison and systematic review

Differential excretion of leucocyte granule components in inflammatory bowel disease: implications for pathogenesis

Neutrophil extracellular traps and its implications in inflammation: an overview

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis

Neutrophil extracellular traps license macrophages and Th17 cells for cytokine production in atherosclerosis

NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis

Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus

Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps

Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis

Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis

Targeting potential drivers of COVID-19: neutrophil extracellular traps

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Extracellular DNA, neutrophil extracellular traps, and inflammasome activation in severe asthma

Neutrophil extracellular traps in pediatric inflammatory bowel disease

In vivo imaging of neutrophil extracellular traps (NETs): visualization methods and outcomes

Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis

Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps

Phosphotidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease

REDD1/autophagy pathway is associated with neutrophil-driven IL-1b inflammatory response in active ulcerative colitis

Neutrophil extracellular traps sustain inflammatory signals in ulcerative colitis

Anti-TNF-alpha therapy suppresses proinflammatory activities of mucosal neutrophils in inflammatory bowel disease

Flavonoids and 5-aminosalicylic acid inhibit the formation of neutrophil extracellular traps

Neutrophil extracellular traps induce intestinal damage and thrombotic tendency in inflammatory bowel disease

Neutrophil extracellular traps exacerbate inflammatory responses and thrombotic tendency in both a murine colitis model and patients with inflammatory bowel disease

Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps

Neutrophil extracellular traps in ulcerative colitis: a proteome analysis of intestinal biopsies

Metaproteomics of fecal samples of Crohn's disease and ulcerative colitis

Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients

Elevated fecal calprotectin levels during necrotizing enterocolitis are associated with activated neutrophils extruding neutrophil extracellular traps

Diabetes primes neutrophils to undergo NETosis, which impairs wound healing

Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis

Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease

Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with Crohn's disease

Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease

Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils

On the origin of low-density neutrophils

Ultra-pure isolation of low density neutrophils casts doubt on their exceptionality in health and disease

CD177þ neutrophils and its correlation with mucosal impairment in patients with inflammatory bowel disease

Analysis of the expression of NB1 antigen using two monoclonal antibodies

Differential expression of granulopoiesis related genes in neutrophil subsets distinguished by membrane expression of CD177

Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression

IL-17-producing peripheral blood CD177þ neutrophils increase in allergic asthmatic subjects

Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators

Human cytomegalovirus delays neutrophil apoptosis and stimulates the release of a prosurvival secretome

Delay of neutrophil apoptosis in acute coronary syndromes

Neutrophil apoptosis is delayed in patients with inflammatory bowel disease

Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease

Neutrophil ageing is regulated by the microbiome

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease

Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1b-mediated familial Mediterranean fever attack through autophagy-driven neutrophil extracellular traps

Key advances in the clinical approach to ANCA-associated vasculitis

Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease

Serological markers of inflammatory bowel disease

Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype

Pathogenesis of ANCA vasculitis

Detection by flow cytometry of anti-neutrophil cytoplasmic antibodies in a novel approach based on neutrophil extracellular traps

Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa

Mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern released during active IBD

Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps

Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus

Circulating mitochondrial DAMPs cause inflammatory responses to injury

Mitochondrial DNA in innate immune responses and inflammatory pathology

Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery

Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils

Thrombosis in inflammatory bowel diseases: what's the link?

Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease

Neutrophil extracellular traps exert both proand anti-inflammatory actions in rheumatoid arthritis that are modulated by C1q and LL-37

Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines

Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing

Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor

Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer

Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice

Peptidylarginine deiminase inhibitor suppresses neutrophil extracellular trap formation and MPO-ANCA production

Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodiuminduced colitis

Neutrophil elastase inhibitor suppresses IL-17 based inflammation of murine experimental colitis

A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications

DNase in cystic fibrosis: the challenge of assessing response and maximising benefit

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Anakinra for rheumatoid arthritis: a systematic review

Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases

Signal inhibitory receptor on leukocytes-1 limits the formation of neutrophil extracellular traps, but preserves intracellular bacterial killing